Literature DB >> 805062

Hemoglobin solution as a plasma expander.

S F Rabiner.   

Abstract

Stroma-free homoglobin solution has received extensive experimental trials in dogs and nonhuman primates. It has been shown to have no coagulant activity and to have no deleterious effect on renal function. Also pathological examination of autopsy and biopsy specimens fails to demonstrate any kidney damage after infusion of large amounts of stroma-free hemoglobin solution. In vivo data would also indicate that the solution can both carry oxygen and liberate it into tissues despite the fact that its in vitro oxygen dissociation curve is shifted to the left. Animals can be maintained with a 3% hematocrit after exchange transfusion with hemoglobin solution, without any significant fall in blood pressure or rise in central venous pressure. This is not true for nonoxygen carrying plasma expanders. Hemoglobin solution has also been shown to have an effect on blood rheology which would tend to increase flow through microcirculation. We conclude that stroma-free hemoglobin solution has potential for use as a plasma expander for treatment of hemorrhagic and possibly other types of shocks, as well as other uses.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 805062

Source DB:  PubMed          Journal:  Fed Proc        ISSN: 0014-9446


  4 in total

1.  Soluble dextran-hemoglobin complex as a potential blood substitute.

Authors:  S C Tam; J Blumenstein; J T Wong
Journal:  Proc Natl Acad Sci U S A       Date:  1976-06       Impact factor: 11.205

Review 2.  Blood and plasma substitutes--plasma expansion and oxygen transport properties.

Authors:  K Waxman; K K Tremper; G R Mason
Journal:  West J Med       Date:  1985-08

3.  Artificial red cells with crosslinked hemoglobin membranes.

Authors:  T A Davis; W J Asher; H W Wallace
Journal:  Appl Biochem Biotechnol       Date:  1984       Impact factor: 2.926

Review 4.  Current status of erythrocyte substitutes.

Authors:  G P Biro
Journal:  Can Med Assoc J       Date:  1983-08-01       Impact factor: 8.262

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.